Unique ID issued by UMIN | UMIN000019476 |
---|---|
Receipt number | R000022524 |
Scientific Title | Defining a novel law of glucose homeostasis under Dapagliflozin usage by mathematical model approach |
Date of disclosure of the study information | 2016/01/01 |
Last modified on | 2016/02/22 11:51:52 |
Defining a novel law of glucose homeostasis
under Dapagliflozin usage
by mathematical model approach
Defining a novel law of glucose homeostasis
under Dapagliflozin usage
by mathematical model approach
Defining a novel law of glucose homeostasis
under Dapagliflozin usage
by mathematical model approach
Defining a novel law of glucose homeostasis
under Dapagliflozin usage
by mathematical model approach
Japan |
diabetes mellitus
Endocrinology and Metabolism |
Others
NO
Finding a new blood glucose homeostasis law using 100 person's time series data ,which were obtained during OGTT or Hyperinsulinemic euglycemic clamp
Efficacy
Exploratory
Others
Not applicable
Finding a new blood glucose homeostasis law
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Prevention
Medicine |
One hundred person's time series boold glucose value or hormons concentration data, which were obtained immediately after taking SGLT2 inhibitor.
20 | years-old | <= |
75 | years-old | > |
Male and Female
1)Volunteers or Type 2 diabetes mellitus who has not been administered SGLT2 inhibitors
2) 20-75 years old,
3) having a will to attend this study
1) pregnant or breast-feeding women
2) insulin antibody positive (>10 arbitrary unit)
3) having allergy or skin trouble for oral hypoglycemic agants or insulin
4) type 1 diabetes or other specific type of diabetes
5) severe liver dysfunction (transaminase twice over the normal limit)
6) severe renal dysfunction (eGFR < 50)
7) severe heart failure (NYHA>2)
8) long-acting insulin, long-acting GLP-1 RA, or long-acting DPP-4 inhibitor user
9) psychological disorder
10) recent severe hypoglycemia or hypoglycemia unawareness
11) contraindication of dapagliflozine
11) others inappropriate for this study
100
1st name | |
Middle name | |
Last name | Kazuhiko Sakaguchi |
Kobe University Graduate School of Medicine
Division of Diabetes and Endocrinology Department of Internal Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe
81-76-382-5861
kzhkskgc@med.kobe-u.ac.jp
1st name | |
Middle name | |
Last name | Kazuhiko Sakaguchi |
Kobe University Graduate School of Medicine
Division of Diabetes and Endocrinology Department of Internal Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe
81-76-382-5861
kzhkskgc@med.kobe-u.ac.jp
Division of Diabetes and Endocrinology Department of Internal Medicine,Kobe University Graduate School of Medicine
AstraDeneca, Ono pharmaceutical Co., LTD
Other
NO
神戸大学医学部附属病院(兵庫県)
2016 | Year | 01 | Month | 01 | Day |
Unpublished
Terminated
2015 | Year | 10 | Month | 23 | Day |
2016 | Year | 01 | Month | 01 | Day |
2015 | Year | 10 | Month | 23 | Day |
2016 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022524
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |